Spots Global Cancer Trial Database for renal medullary carcinoma
Every month we try and update this database with for renal medullary carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | NCT00027820 | Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child... | Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M... | - | Fred Hutchinson Cancer Center | |
| Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer | NCT06161532 | Small Cell Carc... Small Cell Carc... Squamous Cell C... Squamous Cell C... Primary Adenoca... Primary Adenoca... Renal Medullary... Squamous Cell C... | Sacituzumab gov... Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | NCT04537715 | All Malignancie... Advanced Malign... Hematologic Mal... Solid Tumor Follicular Lymp... Non-Hodgkin Lym... Diffuse Large B... Epithelioid Sar... Synovial Sarcom... Renal Medullary... Mesothelioma Rhabdoid Tumor | Tazemetostat Itraconazole Tazemetostat Rifampin | 18 Years - | Ipsen | |
| A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | NCT05355753 | Synovial Sarcom... Soft Tissue Sar... | CFT8634 | 12 Years - | C4 Therapeutics, Inc. | |
| Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla | NCT05347212 | Carcinomas Renal Medullary... | Nivolumab Relatlimab | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma | NCT06302569 | Bellini Carcino... Collecting Duct... Renal Medullary... | Pembrolizumab +... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study to Assess the Long-term Safety of Tazemetostat | NCT02875548 | Diffuse Large B... Follicular Lymp... Synovial Sarcom... Epitheliod Sarc... Mesothelioma Advanced Solid ... Renal Medullary... Non-Hodgkin Lym... | Tazemetostat | 18 Years - | Ipsen | |
| Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma | NCT06302569 | Bellini Carcino... Collecting Duct... Renal Medullary... | Pembrolizumab +... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
